International Stem Cell Corporation · OTC:ISCO

International Stem Cell — Investor Presentation (December 2015)

12 slides from International Stem Cell's investor presentation, Dec 17, 2015

  1. Slide 1: Cells for Therapy and Research

    Cells for Therapy and Research OTCQB ISCO www.internationalstemcell.com International Stem Cell Corporation bd@intlstemcell.com 5950 Priestly Drive 1-760-940-6383 Carlsbad CA 92008

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement This presentation includes certain statements, estimates and projections with respect to the anticipated future business and performance of the Company, which are collectively referred to as forward-looking statements. Forward-looking statements reflect various assumptions

  3. Slide 3: Cells for Therapy and Research

    Cells for Therapy and Research Unique stem cell platform Proprietary Robust clinical and pre-clinical pipeline Scalable addressing large Ethical unmet medical needs Neural stem cells Parkinson’s disease Stroke Commercially Eye diseases successful human cell manufacturing subsidiary $6 MM revenue Cor

  4. Slide 4: Intellectual Property

    Intellectual Property Freedom to operate in major jurisdictions Potential competitive advantages in EU 220 patents, applications and licenses • Pluripotent cell development • Cell banking • Manufacturing methods • Cell differentiation • Treating diseases Numerous publications • Nature’s Scientific R

  5. Slide 5: Broad Pipeline of Targets

    Broad Pipeline of Targets Clinical success unlocks significant value Pre- Indication IND Phase I/II clinical Parkinson’s disease Ischemic stroke Cartilage / Spinal disk Retinal blindness Corneal blindness 5

  6. Slide 6: Parkinson's Disease

    Parkinson’s Disease # 2 Neurodegenerative disease Limited treatment options (symptomatic only) ‒ About 1 million people in US have PD ‒ Direct and indirect costs ~$25 billion ‒ Rarely diagnosed prior to 50 years of age ‒ Hallmark motor symptoms  Bradykinesia (slow movement)  Rigidity  Tremor ‒ Mo

  7. Slide 7: Therapeutic Approach

    Therapeutic Approach • Neural Stem Cells derived from proprietary platform • Established bank of HLA compatible stem cells • Dual mechanism of action: • Inflammation reduction • Dopaminergic neurons replacement • Transplantation directly into midbrain • Proven efficacy Differentiate Expand Thaw On-s

  8. Slide 8: 12-Month Primate Data

    12-Month Primate Data Transplanted Cells Integrate Dopamine Fiber Innervation Non-Human Primates (n=18) 12 months Control Treatment 8

  9. Slide 9: 12-Month Primate Data

    12-Month Primate Data Dopamine levels post mortem Stable Parkscores and Healthy Behavior for duration of the study Functional activity demonstrated in disease model primates 12/16/2015 9

  10. Slide 10: Phase 1 Clinical Trial – 2H 2015

    Phase 1 Clinical Trial – 2H 2015 12 month single arm dose escalating study ‒ Doses based on primate data ‒ 12 subjects with idiopathic Parkinson’s disease ‒ UPDRS < 49 in off-phase Primary endpoints: ‒ Stable on medications ‒ Safety  No worsening of symptoms  Brain lesions (MRI) ‒ Efficacy  Impro

  11. Slide 11: 2016/2017 Milestones

    2016/2017 Milestones Program 1H 2016 2H 2016 1H 2017 Phase I/IIa: • 6 months • Full clinical • Patient clinical data Parkinson’s disease enrollment data • US IND • Dosing (Phase IIb) • License Ophthalmology w/Rohto 11

  12. Slide 12: Financials

    Financials Trading symbol OTCQB ISCO Headquarters Carlsbad, CA Stock price $4.36 52 week range $1.25 - $12.30 Market cap. $25.3 million Ave. vol. (30 day) 14,307 Long-term debt $0 Full time employees 40 12

International Stem Cell — Investor Presentation (December 2015) on 6ix